|Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial|
D Cameron, J Brown, R Dent, C Jackisch, J Mackey, X Pivot, GG Steger, ...
The lancet oncology 14 (10), 933-942, 2013
|PET-CT surveillance versus neck dissection in advanced head and neck cancer|
H Mehanna, WL Wong, CC McConkey, JK Rahman, M Robinson, ...
New England Journal of Medicine 374 (15), 1444-1454, 2016
|Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others|
J Bartlett, J Bayani, A Marshall, JA Dunn, A Campbell, C Cunningham, ...
JNCI: Journal of the National Cancer Institute 108 (9), 2016
|PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data|
PN Aguiar Jr, RA De Mello, P Hall, H Tadokoro, G Lima Lopes
Immunotherapy 9 (6), 499-506, 2017
|Economic evaluation of genomic test–directed chemotherapy for early-stage lymph node–positive breast cancer|
PS Hall, C McCabe, RC Stein, D Cameron
Journal of the National Cancer Institute 104 (1), 56-66, 2012
PS Hall, DA Cameron
European Journal of Cancer 45 (1), 12-18, 2009
|Updated cost-effectiveness analysis of trastuzumab for early breast cancer|
PS Hall, C Hulme, C McCabe, Y Oluboyede, J Round, DA Cameron
Pharmacoeconomics 29 (5), 415-432, 2011
|Cost effectiveness modelling for health technology assessment|
R Edlin, C McCabe, C Hulme, P Hall, J Wright
|Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer|
R Bell, J Brown, M Parmar, M Toi, T Suter, GG Steger, X Pivot, J Mackey, ...
Annals of Oncology 28 (4), 754-760, 2017
|AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): a randomised, double-blind, placebo-controlled …|
P Schmid, J Abraham, S Chan, D Wheatley, M Brunt, G Nemsadze, ...
J Clin Oncol 36 (15_suppl), 1007, 2018
|Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial|
J Bartlett, P Canney, A Campbell, D Cameron, J Donovan, J Dunn, H Earl, ...
Clinical oncology 25 (2), 109-116, 2013
|Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle‐invasive transitional cell carcinoma of the bladder|
C Blick, P Hall, T Pwint, F Al‐Terkait, J Crew, T Powles, V Macaulay, ...
Cancer 118 (16), 3920-3927, 2012
|OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.|
RC Stein, JA Dunn, JMS Bartlett, AF Campbell, A Marshall, P Hall, ...
Health technology assessment (Winchester, England) 20 (10), 1, 2016
|Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data|
PS Hall, P Hamilton, CT Hulme, DM Meads, H Jones, A Newsham, J Marti, ...
British journal of cancer 112 (5), 948-956, 2015
|Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies?|
R Edlin, P Hall, K Wallner, C McCabe
Value in health 17 (4), 438-444, 2014
|A randomised controlled trial and cost-effectiveness analysis of high-frequency oscillatory ventilation against conventional artificial ventilation for adults with acute …|
R Lall, P Hamilton, D Young, C Hulme, P Hall, S Shah, I MacKenzie, ...
NIHR Journals Library, 2015
|6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial|
HM Earl, L Hiller, AL Vallier, S Loi, K McAdam, L Hughes-Davies, ...
The Lancet 393 (10191), 2599-2612, 2019
|Expected net present value of sample information: from burden to investment|
PS Hall, R Edlin, S Kharroubi, W Gregory, C McCabe
Medical Decision Making 32 (3), E11-E21, 2012
|Navigating time and uncertainty in health technology appraisal: would a map help?|
C McCabe, R Edlin, P Hall
Pharmacoeconomics 31 (9), 731-737, 2013
|PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned …|
H Mehanna, CC McConkey, JK Rahman, WL Wong, AF Smith, C Nutting, ...
Health Technology Assessment, 2017